Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase III ramucirumab lung cancer trial meets primary endpoint of overall survival

Feb. 20, 2014

FDA approves California Stem Cell's phase II stem trial for ovarian cancer

Feb. 19, 2014

Pierre Fabre obtains worldwide rights to immune checkpoint modulator from Aurigene

Feb. 14, 2014

Generex provides update on phase II AE-37 trial in breast cancer

Feb. 13, 2014

KaloBios begins phase II expansion portion of KB-004 study

Feb. 12, 2014

First patient receives PDS Biotechnology's PDS-0101 in phase I trial

Feb. 12, 2014

Scancell's SCIB-1 receives FDA orphan drug status for metastatic melanoma

Feb. 11, 2014

Aduro BioTech begins phase IIb ECLIPSE trial in patients with pancreatic cancer

Feb. 11, 2014

New targeted immunotherapy compounds designed by Shanghai Birdie Biotech

Feb. 11, 2014

Ganymed Pharmaceuticals begins phase I/II trial of IMAB-027 in advanced ovarian cancer

Feb. 11, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.